Latest Breaking News On - Danny bar zohar - Page 10 : comparemela.com

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent

Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent 1 A new company-sponsored, global clinical trial will further assess berzosertib in small cell lung cancer Merck is leading more than ten clinical trials across DNA Damage Response (DDR) pathways in various tumor types Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset in the company s DNA damage response (DDR) inhibitor program and one of the most advanced ATR inhibitors in oncology clinical development industry-wide.

United statesDanish thomasJulissa vianaNational cancer instituteLasker clinical research scholarCancer researchMerck kgaDevelopmental therapeutics branchAmerican cancer societyVertex pharmaceuticalsDevelopment agreementNational institutes of healthMerck pressAmerican cancer society small cell lungUs national cancer instituteGlobal head of development for the healthcare

Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Press release content from PR Newswire. The AP news staff was not involved in its creation. Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer March 16, 2021 GMT Not intended for UK-based media DARMSTADT, Germany, March 16, 2021 /PRNewswire/ Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant of first-line platinum-based chemotherapy. In the study of 159 patients, bintrafusp alfa demonstrated single-agent efficacy and durability with a manageable safety profile after more than nine months of follow-up, with an Independent Review Committee (IRC)-adjudicated objective response rate (ORR) of 10.1% (95% CI: 5.9% to 15.8%) per RECI

United statesPrnewswire merck kgaMilind javleMd anderson cancer centerGroup websiteClinical trial programMerck kgaGlobal head of development for the healthcareMerck kgaaUnited kingdom basedIndependent review committeeCancer centerDanny bar zoharGlobal headBiliary tract cancerClinical trial

GSK, German Merck s $4 2B bintrafusp alfa drug flops again, but companies squint to see glimmers of hope

Mar 16, 2021 4:34am GlaxoSmithKline and Merck KGaA’s bintrafusp alfa failed in second-line patients with locally advanced or metastatic biliary tract cancer. (GSK) Two months after GlaxoSmithKline and Merck KGaA’s oncology asset bintrafusp alfa failed to beat out King Keytruda in certain lung cancers, it has followed up with another disappointment. The bifunctional fusion protein immunotherapy, which is the center of the $4.2 billion deal GSK penned with Merck in 2019, flopped a midstage test on its own treating 159 second-line patients with locally advanced or metastatic biliary tract cancer (BTC). An independent review showed it had an objective response rate (ORR) of just 10.1% , with efficacy hitting below a predefined threshold that would have let it file the drug in that setting.

King keytrudaMilind javleMerck kgaMerck kgaaMd anderson cancer centerCancer centerDanny bar zoharGerman merckPd l1Immuno oncologyClinical trial dataமெர்க் க்கம்ட் ஆண்டர்சன் புற்றுநோய் மையம்புற்றுநோய் மையம்டேனி மதுக்கூடம் ஜோஹார்ஜெர்மன் மெர்க்

Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

CET- Comunicado - ;ultimaHoraHtml += + json.lead + ;}ultimaHoraHtml += ; document.getElementById( urgente ).innerHTML = ultimaHoraHtml; } } }); Not intended for US-, Canada- or UK-based media DARMSTADT, Germany, March 16, 2021 /PRNewswire/ Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) who have failed or are intolerant of first-line platinum-based chemotherapy. In the study of 159 patients, bintrafusp alfa demonstrated single-agent efficacy and durability with a manageable safety profile after more than nine months of follow-up, with an Independent Review Committee (IRC)-adjudicated objective response rate (ORR) of 10.1% (95% CI: 5.9% to 15.8%) per RECIST 1.1. Though single-agent activity was observed,

United statesPrnewswire merckMilind javleGlobal head of development for the healthcareMerck pressMd anderson cancer centerUnited kingdom basedIndependent review committeeCancer centerDanny bar zoharGlobal headBiliary tract cancerBintrafusp alfaClinical trialMerck press releasesContacts media relations

Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesMilind javleMd anderson cancer centerGroup websiteClinical trial programMerck kgaGlobal head of development for the healthcareMerck kgaaCancer centerDanny bar zoharGlobal headBiliary tract cancerClinical trialஒன்றுபட்டது மாநிலங்களில்ம்ட் ஆண்டர்சன் புற்றுநோய் மையம்குழு இணையதளம்